login

Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials

The LancetPublished 1 July 1996
Julie Parsonnet, Ryan A. Harris, Howard M. Hack, Douglas K Owens
Citations332
SJR quartileQ1
SJR score12.11
SNIP22.72

TL;DR

A cost-effectiveness analysis to estimate the costs and benefits associated with screening for H pylori at age 50 and treating those individuals infected with antibiotics found it potentially cost-effective in the prevention of gastric cancer, particularly in high-risk populations.

Abstract

Screening and treatment for H pylori infection is potentially cost-effective in the prevention of gastric cancer, particularly in high-risk populations. Cancer prevention trials are strongly recommended.

Keywords

Medicine